• Biocartis initiates commercialization in Europe of SkylineDx’s innovative Merlin™ Assay (CE-IVD) for melanoma patients

    Thursday September 1st 2022

  • argenx announces European Commission approval of VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis

    Thursday August 11th 2022

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    Tuesday July 5th 2022

  • New agreement paves way for development of first African-owned COVID-19 vaccine

    Tuesday June 21st 2022

  • argenx announces the UK MHRA has granted early access to efgartigimod for generalized myasthenia gravis

    Tuesday May 31st 2022

  • miDiagnostics launches its CE-IVD certified ultra-fast COVID-19 PCR test

    Monday May 2nd 2022

  • Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study

    Tuesday April 5th 2022

  • Jyseleca® approved in Japan for ulcerative colitis

    Monday March 28th 2022

  • Your news here?

  • The fight against cancer intensified thanks to SCK CEN and the IRE

    Monday February 28th 2022

  • miDiagnostics ultra-fast COVID-19 PCR Test succeeds in Brussels Airport pilot study

    Thursday February 17th 2022

  • Medical device Morphemat® wins Gold ‘Business Innovation’ Henry van de Velde Award

    Wednesday February 9th 2022


Strategic Partners